Antipa Minerals Ltd (ASX:AZY)’s good news continues as assay results roll in from its 2021 drill program at the 144-square-kilometre Minyari Dome Project in Western Australia’s Paterson Province.
The project is within 35 kilometres from Newcrest Mining’s Telfer gold-copper-silver mine and mineral processing facility and 54 kilometres along strike from Greatland Gold-Newcrest's Havieron gold-copper development project.
NetScientific PLC (AIM:NSCI) said that portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB)’s treatment for advanced human papillomavirus (HPV) associated head and neck cancer achieved its preliminary objective in early results from a phase 2 trial.
Objective response is achieved by radiographic tumour reduction of 30% or more and was confirmed by two separate measurements among at least four of the first 17 patients.
Chesnara PLC (LSE:CSN) has announced the pricing of its £200mln inaugural debt capital markets issue.
Proceeds from the funding are earmarked for general corporate purposes including investments and acquisitions, the company said in a statement.
Tirupati Graphite PLC (LSE:TGR, OTCQX:TGRHF) said it had resumed operations in Madagascar following damage caused by the severe tropical storm Ana.
Road connectivity to its Vatomina and Sahamamy projects was disrupted, but neither mine suffered any material damage.
Allergy Therapeutics PLC (AIM:AGY) has inked a new £10mln financing facility with its bank, Natwest, expanding upon a prior £7mln overdraft.
It is a three-year facility, expandable for another two years, and the company said it can provide additional security to its current credit facilities.
Cellular Goods PLC (LSE:CBX) said its cannabidiol (CBD) and cannabigerol (CBG) blends are capable of counteracting skin ageing effects equally and, in some cases, more effectively than vitamin c treatments that dominate the multi-billion-dollar market.
Its cannabinoid formulations were also found suitable for sensitive skin, a recently published white paper from the company also confirmed.
Open Orphan PLC (AIM:ORPH, OTC:OPORF) chairman Cathal Friel said a new Covid human characterisation study could be ‘instrumental’ in accelerating the development of future therapeutics.
“New variants, such as Omicron, often mean that vaccines and antivirals have to be quickly re-evaluated to ensure effectiveness,” he said following the release of results from the ground-breaking analysis.